LIPOSORBER® Provides Hope When Drug Therapy Fails™
How LIPOSORBER Offers a Better Way to Lower Cholesterol
LIPOSORBER is an FDA-approved device that removes Low-Density Lipoprotein Cholesterol (LDL-C) and Lipoprotein(a) [Lp(a)] directly from the blood. With approximately 600,000 treatments performed worldwide on over 6,000 patients, it is a trusted and effective solution.
"What to Expect" Patient Videos, Now Available!
We’re excited to share two new video resources on “What to Expect When Starting LIPOSORBER Treatment”—one targeting the adult audience and the other for pediatric patients. These short, patient-friendly videos will walk your patient through the therapy experience, step-by-step, answer questions, and help them feel calm and ready.
Mary N. – Familial Hypercholesterolemia (FH) Patient Story
Proven Success in High-Risk Conditions
We believe in supporting your journey with the best way to lower cholesterol that fits your unique medical profile. Treatment with LIPOSORBER can deliver life-changing results for patients facing severe conditions:
Familial Hypercholesterolemia (FH):
Treatment with LIPOSORBER can help FH patients reduce coronary events by 72%. 2*
Kidney Disease (FSGS):
Treatment with LIPOSORBER has enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.3**
Locate a Treatment Center Near You
Are you a candidate for LIPOSORBER® Therapy?
LIPOSORBER is an FDA approved device that removes low-density lipoprotein cholesterol (LDL-C) and Lipoprotein(a) [Lp(a)] from the blood. Approximately 600,000 treatments have been performed worldwide on over 6,000 patients. Talk to your doctor about whether LIPOSORBER is right for you. Click below to take our quiz and discuss with your doctor.

References
- Kaneka Medical America LLC.,2025 LIPOSORBER LA-15 Instructions for use in Familial Hypercholesterolemia (FH).
- Mabuchi, H et al. “Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia.” Hokuriku-FH-LDL-Apheresis Study Group. The American journal of cardiology vol. 82,12 (1998): 1489-95. doi:10.1016/s0002-9149(98)00692-4.
- Muso, Eri et al. “Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8.
*Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years.
**Based on study that took place over two (2) years.